Albendazole

CLINICAL USE

Treatment ofEchinococcus granulosus
(hydatid disease), in combination with
surgery

Treatment of nematode infections

DOSE IN NORMAL RENAL FUNCTION

Echinococcus granulosus:

>60 kg: 400 mg twice daily for 28 days

<60 kg: 15 mg/kg in 2 divided doses to amaximum of 800 mg daily
Treatment of nematode infections: 400 mg as
a single dose

PHARMACOKINETICS

Molecular weight :
265.3

%Protein binding :
70

%Excreted unchanged in urine :
<1

Volume of distribution (L/kg) :
No data

half-life – normal/ESRD (hrs) :
8–12 (metabolite)/
Probably unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 :
Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :
Unlikely dialysability. Dose as in
normal renal function

HD :
Not dialysed. Dose as in normal renal function

HDF/high flux :
Unknown dialysability. Dose as in
normal renal function

CAV/VVHD :
Unlikely dialysability. Dose as in
normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs
Dexamethasone: increased concentrations

of metabolite of albendazole

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Available on a named patient basis from

IDIS (Zentel®)
Undergoes first pass metabolism

Tags: post-by-auto-php